Notice2021-26630
Supplemental Evidence and Data Request on Emergency Medical Service/911 Workforce Infection Control and Prevention Issues
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 9, 2021
Issuing agencies
Health and Human Services DepartmentAgency for Healthcare Research and Quality
Abstract
The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on Emergency Medical Service/911 Workforce Infection Control and Prevention Issues, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 234 (Thursday, December 9, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 234 (Thursday, December 9, 2021)]
[Notices]
[Pages 70127-70129]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-26630]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Emergency Medical
Service/911 Workforce Infection Control and Prevention Issues
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submissions.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Emergency
Medical Service/911 Workforce Infection Control and Prevention Issues,
which is currently
[[Page 70128]]
being conducted by the AHRQ's Evidence-based Practice Centers (EPC)
Program. Access to published and unpublished pertinent scientific
information will improve the quality of this review.
DATES: Submission Deadline on or before January 10, 2022.
ADDRESSES:
Email submissions: <a href="/cdn-cgi/l/email-protection#a4c1d4c7e4c5ccd6d58accccd78ac3cbd2"><span class="__cf_email__" data-cfemail="6603160526070e1417480e0e1548010910">[email protected]</span></a>.
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement,
Agency for Healthcare Research and Quality, ATTN: EPC SEADs
Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and
Practice Improvement, Agency for Healthcare Research and Quality, ATTN:
EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: Jenae Benns, Telephone: 301-427-1496
or Email: <a href="/cdn-cgi/l/email-protection#7510051635141d07045b1d1d065b121a03"><span class="__cf_email__" data-cfemail="86e3f6e5c6e7eef4f7a8eeeef5a8e1e9f0">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Emergency Medical
Service/911 Workforce Infection Control and Prevention Issues. AHRQ is
conducting this technical brief pursuant to Section 902 of the Public
Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Emergency Medical Service/911 Workforce Infection
Control and Prevention Issues, including those that describe adverse
events. The entire research protocol is available online at: <a href="https://effectivehealthcare.ahrq.gov/products/ems-911-workforce-infection-control/protocol">https://effectivehealthcare.ahrq.gov/products/ems-911-workforce-infection-control/protocol</a>.
This is to notify the public that the EPC Program would find the
following information on Emergency Medical Service/911 Workforce
Infection Control and Prevention Issues helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this indication. In the list, please indicate whether
results are available on <a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> along with the
<a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> trial number.
[ssquf] For completed studies that do not have results on
<a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a>, a summary, including the following elements: Study
number, study period, design, methodology, indication and diagnosis,
proper use instructions, inclusion and exclusion criteria, primary and
secondary outcomes, baseline characteristics, number of patients
screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this indication. In the list, please provide the
<a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> trial number or, if the trial is not registered, the
protocol for the study including a study number, the study period,
design, methodology, indication and diagnosis, proper use instructions,
inclusion and exclusion criteria, and primary and secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this indication and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on indications not
included in the review cannot be used by the EPC Program. This is a
voluntary request for information, and all costs for complying with
this request must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: <a href="https://www.effectivehealthcare.ahrq.gov/email-updates">https://www.effectivehealthcare.ahrq.gov/email-updates</a>.
The technical brief will answer the following questions. This
information is provided as background. AHRQ is not requesting that the
public provide answers to these questions.
Guiding Questions
1. What are the characteristics, incidence, prevalence, and
severity of occupationally-acquired exposures to infectious diseases
for the EMS/911 workforce?
a. How do the incidence, prevalence, and severity of exposures vary
by demographic characteristics (e.g., age, sex, race, ethnicity) of the
workforce?
b. How do the incidence, prevalence, and severity of exposures vary
by workforce characteristics (e.g., training, experience, level of
practice, geographic region)?
2. What are the characteristics and reported effectiveness (i.e.,
benefits and harms) in studies of EMS/911 workforce practices to
prevent infectious diseases?
a. How do workforce practices to prevent infectious diseases vary
by demographic characteristics (e.g., age, sex, race, ethnicity)?
b. How do workforce practices to prevent infectious diseases vary
by workforce characteristics (e.g., training, experience, geographic
region etc.)?
c. How do workforce practices to prevent infectious diseases vary
by practice characteristics (e.g., training, personal protective
equipment (PPE), personnel, and budget requirements)?
d. What is the reported effectiveness (i.e. benefits and harms) in
studies of EMS/911 workforce practices to prevent infectious diseases?
(Outcomes of interest include but are not limited to, incidence,
prevalence, duration, severity, missed work, healthcare utilization,
separation from the workforce, disability, and death from infections.)
3. What are the characteristics and reported effectiveness (i.e.,
benefits and harms) in studies of EMS/911 workforce practices to
recognize and control (e.g., chemoprophylaxis, but excluding treatment)
infectious diseases?
a. How do workforce practices to recognize and control infectious
diseases vary by demographic characteristics (e.g., age, sex, race,
ethnicity) of the EMS/911 workforce?
b. How do workforce practices to recognize and control infectious
diseases vary by workforce characteristics (e.g., training, experience,
level of practice, geographic region)?
c. How do workforce practices to recognize and control infectious
diseases vary by infection recognition and control practice
characteristics (e.g., training, PPE, personnel, and budget
requirements)?
d. What is the reported effectiveness (i.e., benefits and harms) in
studies of EMS/911 workforce practices to recognize and control
infectious disease? (Outcomes of interest include but are not limited
to, incidence, prevalence, duration, severity, missed work, healthcare
utilization, separation from the workforce, disability, and death from
infections.)
[[Page 70129]]
4. What are the context and implementation factors of studies with
effective EMS/911 workforce practices to prevent, recognize and treat
occupationally-acquired infectious diseases? This description might
include distinguishing factors such as workforce training,
surveillance, protective equipment, pre- and post-exposure prophylaxis,
occupational health services, preparedness for emerging infectious
diseases, and program funding.
5. What future research is needed to close existing evidence gaps
regarding preventing, recognizing, and treating occupationally-acquired
infectious diseases in the EMS/911 workforce?
PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and
Settings)
------------------------------------------------------------------------
Inclusion criteria Exclusion criteria
------------------------------------------------------------------------
Population........... <bullet> Emergency medical <bullet> Fire
service workforce fighters and police
including 911 dispatchers personnel not
exposed to or at risk of involved in medical
exposure to an care.
occupationally-acquired
infectious disease as
contact exposure,
respiratory exposure, or
blood-borne exposure.*
Intervention......... <bullet> One or more of <bullet> NA.
the following types of
interventions:
[cir] Training or
education.
[cir] PPE protocols....
[cir] Personnel
policies.
[cir] Budget
allocations.
[cir] Vaccines.........
[cir] Equipment........
Comparison........... <bullet> Any comparison <bullet> Studies
group (for studies that without a comparison
evaluate the group (for studies
effectiveness of an EMS/ that evaluate the
911 workforce practice). effectiveness of an
EMS/911 workforce
practice).
Outcomes............. <bullet> Incidence <bullet> NA.
<bullet> Prevalence.......
<bullet> Duration.........
<bullet> Severity.........
<bullet> Missed work......
<bullet> Healthcare
utilization.
<bullet> Separation from
the workforce.
<bullet> Disability.......
<bullet> Death from
infections.
Timing............... <bullet> Published after
2006 and includes data
after 2006.
Setting.............. <bullet> Conducted in the <bullet> Military
United States. exercises and
drills.
<bullet> Live
evacuations from
another country.
Study design......... <bullet> Experimental and <bullet> No original
non-experimental studies data (Narrative
with comparison groups, reviews,
including pre-post commentaries,
studies. simulation studies).
<bullet> Relevant
systematic reviews..
------------------------------------------------------------------------
* Organisms of interest included but are not limited to SARS-COV2,
influenza, tuberculosis, HIV, and Hepatitis B and C.
Dated: December 3, 2021.
Marquita Cullom,
Associate Director.
[FR Doc. 2021-26630 Filed 12-8-21; 8:45 am]
BILLING CODE 4160-90-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 9, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.